| July 2 |
ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth
Opportunities Conference |
| July 2 |
Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain
Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the
Knee |
| July 2 |
Advanced Life Sciences Announces Supplemental Efficacy Data from
First Pivotal Phase 3 Pneumonia Clinical Trial |
| July 2 |
Ceragenix Compound Shows Promise for Treating Lethal Cystic
Fibrosis Infections |
| July 2 |
Velcade (bortezomib) for Injection Based Induction Therapy
Delivered High Post-Transplant Complete Remission Rate, a Critical
Marker for Increased Overall Survival |
| July 2 |
DOR BioPharma Announces Publication Describing Results of Its
Multivalent Botulinum Toxin Vaccine BT-VACC |
| July 2 |
Major New Review Supports the Broader Potential of CeNeS COMT
Inhibitor Discovery Programme |
| July 2 |
Chi-Med Announces Positive Phase II Proof-of-Concept Data for
HMPL-004 in Ulcerative Colitis |
| July 2 |
Alkermes Announces Positive Results from Phase 1/2 Clinical Study
of ALKS 29 |
| July 2 |
Accelrys to Present to Investors at C.E. Unterberg Emerging Growth
Opportunities Conference |
| July 2 |
Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast
Cancer Risk Prediction in Women with Atypia |
| July 2 |
Ablynx Announces Interim Results of First Nanobody Phase I Study of
ALX-0081 (ANTI-VWF) |
| July 2 |
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH) |
| July 2 |
ENDEAVOR IV Clinical Trial Meets Primary Endpoint |
| July 2 |
Studies of Drug Resistance May Lead to Individual Therapy for Rare
Cancers |
| July 2 |
Beike Biotechnology Study Suggests Adult Stem Cells Show Promise
for Peripheral Vascular Disease |
| July 2 |
Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth
Conference and Attend Pacific Growth Equities Conference |
| July 3 |
Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference |
| July 3 |
Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference |
| July 3 |
Lexicon Develops Antibodies That Lower Triglycerides and
Cholesterol as Potential New Therapy for Heart Disease |
| July 3 |
EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference |
| July 3 |
Skin Rash Actually Signifies Better Outcomes for Pancreatic and
Lung Cancer Patients |
| July 3 |
From Clinical Cancer Research: Rethinking Therapeutic Cancer
Vaccine Trials |
| July 3 |
Researchers Discover Method for Identifying How Cancer Evades the
Immune System |
| July 3 |
Fat Kills Cancer: Turning Stem Cells from Fat Tissue into
Personalized, Cancer-Targeted Therapeutics |
| July 3 |
Cytos Biotechnology Reports Results from Phase IIa Study with
CYT003-QbG10 in Patients Suffering from Atopic Dermatitis |
| July 3 |
Clinical Data From Nymox BPH Drug To Be Presented at American
Urological Association Meeting |
| July 3 |
Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin
Emerging Growth Opportunities Conference |
| July 3 |
Tercica to Present at Investment Conferences |
| July 5 |
Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits
Potential for New Approach to the Treatment and Prevention of
Breast Cancer |
| July 5 |
Rosetta Genomics and Weizmann Institute Scientists Identify Role of
microRNA in Cancer Suppression |
| July 5 |
Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea |
| July 5 |
Avexa's Apricitabine Clinical Trial Update |
| July 5 |
Suven Life Sciences Presenting Pre-clinical data of their
NCE’s SUVN-502 and SUVN-507at International Brain Research
Organization (IBRO) 2007 World Congress of Neuroscience |
| July 5 |
Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst
Congress of the International Society on Thrombosis and Haemostasis |
| July 5 |
Genzyme Announces Results of Clinical Trial of Hylastan |
| July 5 |
Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin
Emerging Growth Conference |
| July 5 |
GTC Biotherapeutics to Webcast Corporate Presentation at the C.E.
Unterberg, Towbin Emerging Growth Life Opportunities Conference |
| July 5 |
Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging
Growth Conference |
| July 5 |
Stanford Researchers Find Brain Pathway of Depression in Rats |
| July 5 |
NIEHS Researchers Identify Enzyme Critical in DNA Replication |
| July 5 |
Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging
Growth Opportunities Conference |
| July 6 |
Study Shows Ixabepilone Demonstrated Clear Activity in Patients
with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,
and Capecitabine |
| July 6 |
TMC125 Showed Significant Virologic Response at Week 24 in
Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3
Trials |
| July 6 |
New Phase 3 Study Published in The Lancet Evaluates Efficacy and
Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination
Therapy in Treatment-Experienced Adults With HIV |
| July 6 |
New Drugs in Multinational Study Show Promise in Fighting
Drug-Resistant HIV |
| July 6 |
SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth
Opportunities Conference |
| July 6 |
BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease |
| July 6 |
DOR BioPharma Announces Issuance of European Patent for Its Oral
Multivalent Botulinum Toxin Vaccine BT-VACC |
| July 6 |
Neurologix to Present at the Third Annual C.E. Unterberg Towbin
Emerging Growth Conference |
| July 6 |
Genzyme Announces Data from First Phase 3 Study of Tolevamer in
Patients with C. difficile Associated Diarrhea |
| July 6 |
Cobalis Reports Phase III Trial Results for PreHistin in Seasonal
Allergic Rhinitis |
| July 6 |
ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth
Opportunities Conference |
| July 9 |
Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings |
| July 9 |
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at
European Society for Medical Oncology |
| July 9 |
TransPharma Medical Announces Positive Results of Phase I Clinical
Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis
Treatment |
| July 9 |
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery |
| July 9 |
MediGene Announces Cancer-Fighting Virus Shows Promise in Early
Clinical Trial |
| July 9 |
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery |
| July 9 |
Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth
Opportunities Conference |
| July 9 |
Response Genetics Announces Publication of a Phase III Clinical
Trial Demonstrating That Low Levels of ERCC-1 Help to Predict
Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer |
| July 9 |
Neose Technologies to Present at C.E. Unterberg, Towbin Emerging
Growth Opportunities Conference |
| July 9 |
New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility |
| July 9 |
Cougar Biotechnology Announces Presentation of Positive CB7630
Clinical Data at ESMO Conference |
| July 9 |
NexMed Announces Completion of Patient Enrollment in Two Pivotal
Phase 3 Studies for Anti-Fungal Product |
| July 9 |
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis |
| July 9 |
YM BioSciences Announces Preclinical Data Confirming Nimotuzumab
Binds to the EGF Receptor and Potentiates Radiotherapy |
| July 9 |
International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis |
| July 9 |
Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference |
| July 9 |
Aptuit Introduces Aptuit IVRS powered by Clarix, a Fully
Web-Integrated Interactive Voice Response System Providing
Customers with Easy Access to Real-Time Data |
| July 9 |
Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial
Targeting System's Success in Mouse Model Reported in Cancer Cell |
| July 10 |
CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of
Action for Ranexa |
| July 10 |
Pieris Progresses Proprietary Asthma Program: Validation of
Pulmonary Delivery of Anticalin-Based Protein Product Candidate |
| July 10 |
Halozyme Therapeutics' Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society |
| July 10 |
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone |
| July 10 |
Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease |
| July 10 |
Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis |
| July 10 |
Protox Announces Positive Clinical Data from Prostate Cancer Study |
| July 10 |
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease |
| July 10 |
Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able
to Heal From Alzheimer's Disease |
| July 10 |
BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease |
| July 10 |
Molecular Target of Bradmer's Neuradiab Further Validated by
Independent Findings |
| July 10 |
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis |
| July 11 |
Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting |
| July 11 |
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial |
| July 11 |
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis |
| July 11 |
Reaction to Avandia Warnings Stronger Among Internists Than
Endocrinologists, According to Study by GfK Market Measures |
| July 11 |
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine |
| July 11 |
Pixantrone Combination Therapy for First-line Treatment of
Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe
Toxicities Including Heart Damage When Compared to
Doxorubicin-based Therapy |
| July 11 |
Clinical Data Suggest Decreased Bleeding Risk in People With Severe
Hemophilia A While Maintaining Factor VIII Levels Above One Percent |
| July 11 |
New Information on the Potential of Plasmin Shared at ISTH Congress |
| July 11 |
Antibiotics Don't Prevent Future Urinary Tract Infections, May
Cause Resistance in Future Infections |
| July 11 |
Positive Aggrastat Results Featured in the Journal of the American
College of Cardiology |
| July 11 |
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis |
| July 11 |
Sygnis Pharma AG announces date for presentation of clinical
results |
| July 11 |
Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs |
| July 11 |
Cell Therapeutics, Inc. Management to Discuss Today's Announcement
of Interim Pixantrone Study Results |
| July 11 |
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis |
| July 11 |
Large Geographic Differences in EpiPen Prescriptions in the U.S.,
From the Journal of Allergy and Clinical Immunology |
| July 12 |
Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer |
| July 12 |
LAB International Announces Positive Results from its Growth
Hormone Releasing Hormone (GHRH) Phase II Trial |
| July 12 |
ISI Announces Regional eCTD Readiness Workshops for Electronic
Submissions |
| July 12 |
Progenics Selected to Present Clinical Results for Novel HIV
Therapy PRO 140 at International Aids Conference |
| July 12 |
CardioVascular BioTherapeutics Completes Pre-clinical Stroke
Research |
| July 12 |
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial |
| July 12 |
Stem Cell Clinic Publishes First Peer Reviewed Paper on Autism Stem
Cell Therapy |
| July 12 |
Carrington Subsidiary DelSite Demonstrates Usefulness of GelSite
Polymer for Therapeutic Delivery of Proteins and Peptides at
Controlled Release Society Meeting |
| July 12 |
City of Hope Selects TrialMaster to support clinical trials |
| July 12 |
Octagon Research Solutions Limited is Granted SME Status in EU |
| July 12 |
Acusphere Presents at Controlled Release Society |
| July 12 |
Celsion Reports Early Success with Second Drug |
| July 12 |
Bayer HealthCare Reports Positive Preclinical Study Results on
Longer-Acting Recombinant Factor VIII Molecules |
| July 12 |
Karo Bio Half Year Report January - June 2007 |
| July 13 |
Cytel Inc. Releases East 5 Clinical Trial Design System |
| July 16 |
Hollis-Eden Pharmaceuticals Reports Initial Results in Phase I
Clinical Trial of HE3286 as New Type II Diabetes Treatment |
| July 16 |
CardioVascular BioTherapeutics to Provide Clinical Trial Details on
July 19 Conference Call |
| July 16 |
Arpida Reports Positive Results of Second Pivotal Phase Iii Trial
with Intravenous Iclaprim in CSSSI |
| July 16 |
Pharsight Releases Drug Model Explorer Version 1.6 |
| July 16 |
Drug Delivery Company Acrux Announces the Results of Its Phase 2
Male Testosterone Replacement Lotion Trial |
| July 16 |
Can-Fite Reports Results of a Phase IIb Clinical Study in
Rheumatoid Arthritis with CF101, an A3 Adenosine Receptor Agonist.
The Results Support Further Clinical Development of CF101 |
| July 16 |
BioLineRx Announces Results of Clinical Receptor-Occupancy Study of
BL-1020, a First in Class GABA-Enhanced Antipsychotic for the
Treatment of Schizophrenia |
| July 16 |
IBM Signs $1.4 Billion Global Strategic Outsourcing Agreement With
AstraZeneca |
| July 16 |
Vernalis Reports Positive Outcome of a Phase IIA Trial of V3381 In
Diabetic Neuropathic Pain |
| July 16 |
Study Finds COPD Patients Taking Inhaled Steroids are at Greater
Risk for Severe Pneumonia |
| July 16 |
Long-Sought Adaptive Trial Predictability Announced: Cytel Inc.,
Tourtellotte Solutions Reveal Integrated Simulators |
| July 16 |
Data Supports Potential Mechanism for Gentium's Defibrotide in
Cancer, Diabetic Nephropathy and Veno-Occlusive Disease |
| July 16 |
Amira Pharmaceuticals Announces Positive Initial Data From a Phase
1 Study of AM103, A Novel Product Candidate for the Treatment of
Respiratory and Cardiovascular Disease |
| July 16 |
New Clinical Results Increase Market Potential of Cytotect |
| July 17 |
Elixir Pharmaceuticals Announces Presentation of Data in Programs
to Treat and Prevent Metabolic Diseases |
| July 17 |
Idera Pharmaceuticals Presents Preclinical Data of Toll-Like
Receptor Antagonists in Rheumatoid Arthritis Models |
| July 17 |
Metabasis Therapeutics Announces CS-917 Phase 2b Clinical Trial
Results and Reports on Status of Pradefovir |
| July 17 |
CVBT Announces Positive Pre-Clinical Results for Protein-Based Drug
Candidate to Treat Osteoporosis |
| July 17 |
Secondary Endpoints of Phase II/III Study Confirm Clear Benefits
from Treatment With removab(R) for Patients with Malignant Ascites |
| July 17 |
AVI BioPharma Announces Positive Pre-Clinical Study Results
Presented at the 26th Annual Meeting of the American Society for
Virology |
| July 17 |
Idera Pharmaceuticals Announces Publication of Study of Toll-Like
Receptor 9 Agonist in Combination with Avastin(R) in Preclinical
Colon Cancer Model |
| July 17 |
Nymox Announces New Drug Data to Be Presented at Upcoming U.S.
Urology Meeting |
| July 17 |
Nextrials Selected by AlwaysOn as an AO 100 Top Private Company
Award Winner |
| July 17 |
Sirtris Pharmaceuticals Presents Results of Studies of SIRT1
Activators at 6th Annual Metabolic Diseases Drug Discovery and
Development World Summit, July 17, 2007 |
| July 18 |
Nymox Announces New Drug Data to Be Presented at Upcoming U.S.
Urology Meeting |
| July 18 |
BioSante Pharmaceuticals Announces New Findings For Potential Bird
Flu Vaccine |
| July 18 |
PPD Completes First-in-Human Trial for Novel Statin |
| July 18 |
Anecortave Acetate Clinical Trial Data for Glaucoma Presented at
World Congress of Glaucoma |
| July 18 |
Purdue Pharma Turns to Microsoft for Document Management Solution |
| July 18 |
TechnoVax Reports on a VLP Vaccine Designed to Protect Against the
Devastating 1918 Pandemic Influenza As Well As a Novel Bivalent VLP
Vaccine Candidate |
| July 18 |
BlueCielo ECM Solutions Releases InnoCielo View 2008 |
| July 18 |
Definiens Reveals an Integrated Data Management Approach For Image
Analysis in Life Sciences Enterprises |
| July 19 |
ImmuneRegen BioSciences, Inc. and Virion Systems, Inc. Continue
Testing Viprovex and Tamiflu as Possible Influenza Co-Treatment |
| July 19 |
Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin's
Lymphoma Meets Primary Endpoint |
| July 19 |
Landmark Cimzia Data in Crohn's Disease Published in New England
Journal of Medicine |
| July 19 |
Positive Preliminary Results of Phase IIb AK Study |
| July 19 |
Pivotal Cimzia Data in Crohn's Disease Published in New England
Journal of Medicine |
| July 20 |
Journal of Clinical Oncology Publishes Data on Zolinza
(vorinostat), Merck's Treatment for Advanced Cutaneous T-cell
Lymphoma |
| July 20 |
Wyeth and Progenics Announce Positive Preliminary Results of Phase
1 Study of New Oral Formulation of Methylnaltrexone |
| July 20 |
Sorel Forge Selects Amadeus eQCM Software Solution |
| July 20 |
GlycoMimetics, Inc. Highlights Advances in Lead Drug Candidate for
Sickle Cell Patients at International Glycobiology Conference |
| July 20 |
Samaritan Announces Positive Preliminary Results in a Phase IIb
Study For Its Novel Oral HIV Entry Inhibitor |
| July 20 |
Improvement Following ADHD Treatment Sustained in Most Children,
But Linked Problems Persist Into Adolescence -- Major Follow-up
Study |
| July 20 |
New Data Show Tekturna and Diovan Used Together Provide Additive
Blood Pressure Reductions |
| July 20 |
Pharsight Releases Drug Model Explorer Version 1.6 |
| July 23 |
ANX-201 Combination Therapy Demonstrates Synergistic Inhibition of
HIV-1 in Preclinical Tests |
| July 23 |
Nventa Announces Publication of Final Results of a Phase 2 Study of
HspE7 in Cervical Dysplasia |
| July 23 |
Xencor Data Published in Journal of Immunology Demonstrate
Selectivity of New Class of Inhibitors for Inflammatory Disease |
| July 23 |
Pluristem's PLX Cells Show Promise in Treating Limb Ischemia |
| July 23 |
Advanced Magnetics Announces Positive Results from Fourth Phase III
Study of Ferumoxytol as an Intravenous Iron Replacement Therapeutic
in Chronic Kidney Disease Patients |
| July 23 |
Paper in Cancer Biology & Therapy Confirms In Vitro Cytotoxic
Effect of Alfacell's Onconase |
| July 23 |
New Interim Results Demonstrate High Response Rate With Fuzeon Plus
Darunavir Regardless of Existing Protease Inhibitor Resistance |
| July 23 |
144-Week Data from Gilead's Study 934 Comparing Truvada to Combivir
Both in Combination with Sustiva Presented At International AIDS
Society Meeting in Sydney |
| July 23 |
MedImmune Announces Interim Phase 1 Study Results for Potential
Asthma Therapy |
| July 23 |
Sygnis Announces Successful Completion of the Clinical IIa Study
for AX200 in Stroke |
| July 23 |
New Data Suggest Boosted Invirase Has Similar Efficacy to Boosted
Lopinavir in HIV Patients at 24 Weeks |
| July 23 |
Baxter Announces Preliminary Phase I/II Data for Seasonal Influenza
Vaccine Candidate |
| July 23 |
SYGNIS successfully completes clinical study IIa for AX200 in
stroke (AXIS) |
| July 24 |
Isentress (raltegravir), an Investigational Oral HIV Integrase
Inhibitor, in Combination Therapy Demonstrated HIV RNA Reduction
Comparable to Efavirenz in Treatment-Naive HIV-Positive Patients |
| July 24 |
Etrials EDC to Interface with Green Mountain Logic Labpas CT |
| July 24 |
Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing
of INCB9471 Provided Potent and Prolonged Antiviral Activity in
HIV-Infected Patients |
| July 24 |
Starpharma Presents Positive Results of Clinical Study of VivaGel
in Men at 4th International AIDS Society Conference |
| July 24 |
Vicriviroc Demonstrates Potent Viral Suppression Through 48 Weeks
of Therapy in ACTG Phase II Study in Treatment-Experienced HIV
Patients |
| July 24 |
Orexigen Therapeutics Reports Top-line 24 Week Results for Phase
IIb Trial of Empatic to Treat Obesity |
| July 24 |
Protalex Announces Preliminary Results in Phase I Clinical Trial |
| July 24 |
Phase Forward and Sentrx Partner to Offer Integrated Drug Safety
Services |
| July 24 |
OrexigenReports Top-line 24 Week Results for Ph IIb EMPATIC?
Obesity Trial |
| July 24 |
Faster-Acting Antidepressants Closer to Becoming a Reality |
| July 25 |
New Head-to-Head Study Comparing Lexiva and Atazanavir Show Similar
Efficacy and Lipid Changes |
| July 25 |
Analysis of Ushercell HIV Trials Reveals Difference in
Seroconversion Groups Not Statistically Significant |
| July 25 |
BioSante Pharmaceuticals Announces Positive Resultsfor its CaP
Technology for Use in Aesthetic Medicine |
| July 25 |
BioSante Pharmaceuticals Announces Positive Results for its CaP
Technology for Use in Aesthetic Medicine |
| July 25 |
Targacept Presents Data from Tridmac Trial Showing Positive Effects
of Mecamylamine as Augmentation Treatment for Depressed Patients |
| July 25 |
Animal Studies Show Promising Therapeutic Dosing Results Using an
Antisense Agent to Treat Heart Disease |
| July 25 |
Actemra monotherapy demonstrates significant clinical benefit in
patients with rheumatoid arthritis |
| July 25 |
Panacos Announces Five Presentations on its Antiviral Programs at
International AIDS Society Conference |
| July 25 |
AVI BioPharma Partner Global Therapeutics Announces Positive
Pre-Clinical Results Shown Using Neugene Antisense Drug in
Prevention of Cardiovascular Restenosis |
| July 25 |
The Journal of Hand Surgery Publishes Initial Phase III Data on
Xiaflextm (formerly known as AA4500), Auxilium's Investigational
Treatment for Patients with Dupuytren's Contracture |
| July 25 |
Fourth Actemra (tocilizumab) Phase III Study Demonstrates
Significant Clinical Benefit in RA Patients |
| July 25 |
Progenics Presents Additional Positive Clinical Results for
HIV-Entry Inhibitor PRO 140 at International AIDS Meeting |
| July 25 |
Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48
Week Data Show |
| July 25 |
Treating HIV-Infected Infants Early Helps Them Live Longer |
| July 25 |
CytoDyn Study of Bird Flu Vaccines Illustrates Subsidiary's Unique
Opportunity |
| July 25 |
Delphian Pharma Announces-Discovery of Novel Anti-tumor Antimitotic
Agents That Also Reverse Tumor Resistance |
| July 26 |
First Peer-Reviewed Preclinical and Early Phase 1 Results for
NKTR-118 (oral PEG-naloxol) to be Presented at Upcoming
Pharmacology and Pain Management Meetings |
| July 26 |
Anti-Tumor Activity and Pharmacokinetic Properties of NKTR-102
(PEG-irinotecan) to be Presented at Upcoming Oncology Meeting |
| July 26 |
Ubisol-Aqua: Coenzyme Q10 May Prevent Toxicity of HIV Drug Therapy |
| July 26 |
OctoPlus Announces Promising Results for Locteron Phase IIa
Clinical Study |
| July 26 |
Avexa Releases ATC Phase IIb Clinical Trial Update |
| July 26 |
Controversy Over Use of Antipsychotic Drugs for Dementia, From the
Harvard Mental Health Letter |
| July 26 |
OctoPlus announces promising results for Locteron Phase IIa
clinical study |
| July 26 |
Yale School of Medicine Shows First Detailed View of Molecular
Structure May Usher in New Class of Cancer Drugs |
| July 27 |
Genaera Corporation Presents New Preclinical Data for Obesity
Compound Trodusquemine (MSI-1436) at CBI Conference |
| July 27 |
Gene Logic Drug Candidate Shows Positive In Vivo Test Results |
| July 27 |
Positive Aggrastat Results Versus Integrilinr Featured in American
Heart Journal |
| July 30 |
Intellect Neurosciences, Inc. Announces the Release of Audited Data
for its Drug Candidate, Oxigon, From a Single Dose Phase I Trial |
| July 30 |
Study Discovers Link Between Increased White Matter in the Brain
and Poor Motor Skills in Children With Autism |
| July 30 |
Can-Fite: Pre-clinical Studies Demonstrate that the Excipients Used
in the Placebo and CF101 Drug Enhanced the Anti-inflammatory Effect
of Methotrexate (MTX) |
| July 30 |
Investigational Anti-Inflammatory Drug Produces Promising Results
in Animal Studies |
| July 30 |
ClinPhone and LabPas CT Agree to Interface |
| July 30 |
AlphaVax Announces Interim Results From Phase 1 Influenza Vaccine
Clinical Trial |
| July 31 |
Infringement Claims Against DATATRAK Dismissed |
| July 31 |
Resveratrol Studies Suggest Broad Implications for SIRT1 Activation
in Neurodegenerative Eye Disorders |
| July 31 |
OncoGenex and Isis Report Encouraging Interim Phase II Data in
Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans |
| July 31 |
New Study Finds Tindamax to be Effective, Well-Tolerated Treatment
for Bacterial Vaginosis |
| July 31 |
Phase Forward Signs Multi-Year Enterprise Agreement with ICON |
| July 31 |
Preliminary Data Add New Mechanistic Insights to Activity of
Anthrax Anti-Toxin, Valortim |
| July 31 |
The International Journal of Cancer Publishes Studies on Generex
Biotechnology's Anti-cancer Activity of Its Immunotherapeutic
Vaccine |
| July 31 |
OncoGenex and Isis Report Encouraging Interim Phase II Data in
Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans |
| July 31 |
Almac Clinical Technologies Launches IXR Express: A new way for
clients to accelerate the clinical trial process |
